Physician profile
Sharon Lee
NPI 1578549093
$741.36
in general payments reported to CMS, 2019-2025
16 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $35.39 · 2021: $91.15 · 2022: $118 · 2023: $158 · 2024: $9.77 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $109.75 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $100.21 | 2023-2025 | |
| Alkermes, INC. | $84.11 | 2023 | Aristada, Lybalvi |
| Bayer Healthcare Pharmaceuticals INC. | $73.73 | 2021-2025 | |
| Therapeuticsmd, INC. | $73.68 | 2019-2022 | |
| Pfizer INC. | $71.66 | 2020-2022 | |
| Gynesonics, INC. | $49.75 | 2022 | |
| Amgen INC. | $49.09 | 2019 | |
| Exeltis, USA INC. | $28.89 | 2019-2025 | Slynd |
| Agile Therapeutics, INC. | $16.54 | 2021 | |
| Renovia INC | $15.29 | 2021 | |
| Astellas Pharma US INC | $14.96 | 2023 | Veozah |
| Bausch Health US, LLC | $14.46 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.67 | 2019 | |
| Avion Pharmaceuticals | $12.79 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.